Acadian Asset Management LLC Grows Stock Holdings in Insulet Corporation $PODD

Key Points

• Acadian Asset Management LLC increased its stake in Insulet Corporation by 374.1% during Q1, owning 54,456 shares valued at approximately $14.3 million.
• Several hedge funds also raised their positions in Insulet, with most showing slight increases in ownership percentages throughout the same quarter.
• Research firms have upgraded Insulet's stock ratings, with a consensus "Moderate Buy" rating and an average price target of $335.12 from various analysts.

Acadian Asset Management LLC grew its position in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 374.1% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,456 shares of the medical instruments supplier's stock after purchasing an additional 42,969 shares during the period. Acadian Asset Management LLC owned approximately 0.08% of Insulet worth $14,295,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the company. Nissay Asset Management Corp Japan ADV grew its position in shares of Insulet by 0.6% during the 1st quarter. Nissay Asset Management Corp Japan ADV now owns 8,462 shares of the medical instruments supplier's stock valued at $2,222,000 after purchasing an additional 48 shares in the last quarter. Brooklyn Investment Group grew its position in shares of Insulet by 7.0% during the 1st quarter. Brooklyn Investment Group now owns 795 shares of the medical instruments supplier's stock valued at $209,000 after purchasing an additional 52 shares in the last quarter. OLD National Bancorp IN grew its position in shares of Insulet by 6.7% during the 1st quarter. OLD National Bancorp IN now owns 880 shares of the medical instruments supplier's stock valued at $231,000 after purchasing an additional 55 shares in the last quarter. Cooper Financial Group grew its position in shares of Insulet by 5.7% during the 1st quarter. Cooper Financial Group now owns 1,079 shares of the medical instruments supplier's stock valued at $283,000 after purchasing an additional 58 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB grew its position in shares of Insulet by 23.1% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 314 shares of the medical instruments supplier's stock valued at $82,000 after purchasing an additional 59 shares in the last quarter.

Insider Buying and Selling at Insulet

In other Insulet news, SVP Prem Singh sold 687 shares of the business's stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the sale, the senior vice president directly owned 3,456 shares of the company's stock, valued at $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Laetitia Cousin sold 797 shares of the business's stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the sale, the senior vice president directly owned 3,890 shares of the company's stock, valued at $1,356,870.90. This represents a 17.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.39% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on PODD. Wall Street Zen upgraded shares of Insulet from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Raymond James Financial reaffirmed an "outperform" rating and set a $360.00 price objective (up from $328.00) on shares of Insulet in a report on Tuesday, May 27th. Wells Fargo & Company lifted their price objective on shares of Insulet from $330.00 to $350.00 and gave the stock an "overweight" rating in a report on Friday, August 8th. Canaccord Genuity Group lifted their price objective on shares of Insulet from $331.00 to $353.00 and gave the stock a "buy" rating in a report on Friday, August 8th. Finally, Oppenheimer lifted their price objective on shares of Insulet from $324.00 to $365.00 and gave the stock an "outperform" rating in a report on Monday. Sixteen equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $335.12.

Insulet Stock Performance

Insulet stock opened at $337.94 on Friday. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. The company has a market capitalization of $23.79 billion, a PE ratio of 102.72, a P/E/G ratio of 2.80 and a beta of 1.36. The firm has a fifty day simple moving average of $310.77 and a two-hundred day simple moving average of $291.47. Insulet Corporation has a twelve month low of $225.28 and a twelve month high of $353.50.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, topping the consensus estimate of $0.92 by $0.25. The business had revenue of $649.10 million during the quarter, compared to the consensus estimate of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm's revenue for the quarter was up 32.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Research analysts expect that Insulet Corporation will post 3.92 EPS for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.